LAVAL, QC, ROCKVILLE, MD
and CAMBRIDGE, United Kingdom,
Sept. 4, 2019 /CNW Telbec/
- Prometic Life Sciences Inc. (TSX: PLI)
(OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused
on developing novel therapeutics to treat unmet needs in patients
with liver, respiratory and kidney disease, today announced that
members of the management team will provide a business overview and
update at the H.C. Wainwright & Co. 21st Annual Global
Investment Conference at 11:15 EDT on Tuesday, September 10, 2019 in New York, USA.
The presentation will be webcast live on the Webcasts
page of the Investors & Media section of Prometic's
website, or by following the links below in your web browser. An
archived replay of the webcast will be available on Prometic's
website for at least 7 days after the live event concludes.
http://wsw.com/webcast/hcw5/pli/
About Prometic
Prometic (www.prometic.com) is an innovative biopharmaceutical
company with a broad pipeline of small molecule therapeutics
under development to treat unmet needs in patients with liver,
respiratory and kidney disease, with a focus on rare or
orphan diseases. Prometic's differentiated research involves the
study of several G-protein-coupled-receptors, GPR40,
GPR120 and GPR84, known as free fatty acid receptors
(FFAR's). These drug candidates have a
multiple mode-of-action as agonists ("stimulators") of
GPR40 and GPR 120, and antagonists ("inhibitors") of
GPR84. Our lead drug candidate, PBI-4050, is expected to enter
Phase 3 clinical studies for the treatment of Alström
Syndrome after approval by the FDA and EMA. A second drug
candidate, PBI-4547, is expected to enter Phase 1 clinical studies
in 2019.
Prometic also has leveraged its experience in bioseparation
technologies to isolate and purify biopharmaceuticals from human
plasma. The lead plasma-derived therapeutic product is
RyplazimTM (plasminogen) which the Company expects to
file a BLA with the US FDA the first half of 2020 seeking approval
to treat patients with congenital plasminogen deficiency. The
Company also operates a contract development and manufacturing
operation in the United Kingdom,
deriving revenue through sales of affinity chromatography
media.
Prometic has active business operations in Canada, the United
States, Isle of Man and the
United Kingdom.
Forward Looking Statements
This presentation contains forward-looking statements about
Prometic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, Prometic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Prometic
to take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or
results to materially differ from our current expectations in the
Annual Information Form for the year ended December 31, 2018, under the heading "Risks and
Uncertainties related to Prometic's Business". As a result, we
cannot guarantee that any forward-looking statement will
materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of
future events or for any other reason, unless required by
applicable securities laws and regulations. All amounts are in
Canadian dollars unless indicated otherwise.
For more information, please visit www.prometic.com.
SOURCE ProMetic Life Sciences Inc.